NCT06433609View on ClinicalTrials.gov

Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

131

Participants

Timeline

Start Date

June 30, 2024

Primary Completion Date

July 31, 2027

Study Completion Date

November 30, 2027

Conditions
Advanced Breast Cancer
Interventions
DRUG

SHR-A1811

Via intravenous infusion

DRUG

SHR-A1921

Via intravenous infusion

DRUG

Adebrelimab

Via intravenous infusion

Trial Locations (1)

102200

Beijing GoBroad Hospital, Beijing

All Listed Sponsors
lead

Beijing GoBroad Hospital

OTHER

NCT06433609 - Study of ADCs Combined With Adebrelimab in HER2-negative Advanced Breast Cancer | Biotech Hunter | Biotech Hunter